Pfm Health Sciences, LP Esperion Therapeutics, Inc. Transaction History

Pfm Health Sciences, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$34.47 - $47.53 $53.6 Million - $73.9 Million	-1,555,112 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$40.1 - $52.33 $2.89 Million - $3.77 Million	-71,967 Reduced 4.42%	1,555,112 $72.3 Million
Q1 2019 May 15, 2019	SELL	$40.11 - $53.57 $10.1 Million - $13.5 Million	-251,924 Reduced 13.41%	1,627,079 $65.3 Million
Q4 2018 Feb 14, 2019	SELL	$36.99 - $59.11 $3.37 Million - $5.39 Million	-91,131 Reduced 4.63%	1,879,003 $86.4 Million
Q3 2018 Nov 13, 2018	SELL	$40.74 - $51.41 $20 Million - $25.2 Million	-490,023 Reduced 19.92%	1,970,134 $87.4 Million
Q2 2018 Aug 14, 2018	BUY	$36.2 - $76.4 $48.2 Million - $102 Million	1,330,159 Added 117.71%	2,460,157 $96.4 Million
Q1 2018 May 15, 2018	BUY	$65.94 - $80.76 $17.1 Million - $21 Million	259,896 Added 29.87%	1,129,998 $81.7 Million
Q4 2017 Feb 14, 2018	BUY	$43.47 - $67.43 $14 Million - $21.7 Million	321,420 Added 58.58%	870,102 $57.3 Million
Q3 2017 Nov 14, 2017	BUY	$43.8 - $52.77 $24 Million - $29 Million	548,682	548,682 $27.5 Million

207

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $155M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Pfm Health Sciences, LP, based on Form 13F filings with the SEC.

Stay updated on Pfm Health Sciences, LP with notifications on news.